Company news: Edelman aquires firm in Vietnam

Share this article:
PR firm Edelman announced Tuesday that it is increasing its reach to include Vietnam. The indie PR giant is poised to acquire AVC Communications, pending government approval. The new company will be called AVC Edelman and will report to Bob Grove, managing director of Edelman Southeast Asia. The PR firm said in a statement that Vietnam is a key location, having tripled its GDP over the last decade.  Edelman says it projects the country's GDP growth will hit 5% to 6% this year.

Wiley-Blackwell is adding 44 titles to its roster of publications. The company said in statement that 16 of the publications are new to the market, and 40 are being published in collaboration with other organizations. The acquisition will add eight titles to its open access program, which publishes primary research. The American Counseling Association, International Reading Association, and TESOL International Association are among the groups with journals that are part of this initiative.

The FDA said labels on statins will now advise patients and doctors that the drugs have been linked to memory loss, forgetfulness and confusion, along with an increased risk for type 2 diabetes. The FDA also says lovastatin may interact with other medications and increase the risk of muscle damage. The changes also include an omission: labels will no longer recommend routine liver enzyme monitoring. Americans bought over $26 billion of the top five drugs in the statin category for the year ended October 31, 2011, according to Wolters Kluwer Pharma Solutions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.